Management of iliofemoral thrombosis in a pregnant patient with heparin resistance

Archives of Internal Medicine

Volumn 157, Issue 7, 1997, Pages 815-816

  Anand, Sonia S ^a   Brimble, Scott ^a   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; ECHOGRAPHY; FEMALE; HEPARINIZATION; HUMAN; ILIAC VEIN; IMPEDANCE PLETHYSMOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; PREGNANCY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030892092     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.1997.00440280157015     Document Type: Article

References (14)

1. Kaunitz AM, Hughes JM, Grimes DA, Smith JC. Causes of maternal mortality in the United States. Obstet Gynecol. 1985;65:605-612.
2. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation. 1996;93:2212-2245.
3. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 1995;108(suppl):305S-311S.
4. Lensing A, Hirsh J, Buller H. Diagnosis of venous thrombosis. In: Colman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott; 1994:1297-1321.
5. Ginsberg JS, Hirsh J, Marder V. Thrombotic and hemorrhagic complications in the obstetric patient. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott; 1994:981-987.
6. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins. Thromb Haemost. 1992;67:639-643.
7. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304.
8. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost. 1993;70:625-630.
9. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res. 1984;34:557-560.
10. Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987;57:234.
11. Omri A, Delaloye JF, Anderson H, Bachmann F. Low molecular weight heparin Novo (LHN-1 ) does not cross the placenta during the second trimester of . pregnancy. Thromb Haemost. 1989;61:55-56.
12. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
13. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445.
14. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.